Richard B. Lipton, MD

Neurologist
Albert Einstein College of Medicine, Bronx, NY, USA

Poster(s):

• (10) Economic impact of early vs. late initiation of atogepant for the preventive treatment of migraine
  Wednesday, October 29, 2025

• (58) Efficacy and Safety of Symbravo® (MoSEICTM meloxicam and rizatriptan) in Participants With Migraine Experiencing an Inadequate Response to Oral CGRP Inhibitors: Topline Results From the EMERGE Trial
  Wednesday, October 29, 2025

• (131) Impact of triptan insufficient response on medication use, health care utilization, and costs: a retrospective claims study
  Wednesday, October 29, 2025

• (132) Health care resource utilization and economic burden in patients cycling through multiple triptans for migraines: a retrospective analysis
  Wednesday, October 29, 2025

• (356) Evaluation of unmet needs and quality-of-care indicators among patients with migraine in the United States: 2021–2022
  Wednesday, October 29, 2025